What is Auxulin?

Type 1 and type 2 diabetic patients face a challenging balancing act between hypoglycemic and hyperglycemic events in their daily lives. Hyperglycemia (high blood sugar) can cause unpleasant symptoms which include increased thirst, headaches, fatigue, and reduced productivity. For type 1 diabetics, hyperglycemia has been treated with the same approach for the past century: take insulin, drink water, and wait for hours for blood glucose levels to return to normal. Uncontrolled hyperglycemia can lead to diabetic ketoacidosis, which is the leading cause of death among young type 1 diabetic patients, with an annual hospitalization rate of 2%.
While there are various over-the-counter treatments for hypoglycemia, such as juice, candy, or glucose tablets, there is no such option for high blood sugar. Auxulin is the first and only supplement to treat hyperglycemia. By augmenting insulin, Auxulin aids in overcoming insulin resistance. Insulin resistance is an inherent trait in hyperglycemia, with said resistance being greater at higher blood sugar levels. Auxulin's patented formulation was created to address the underlying, untreated causes of hyperglycemia in safe, convenient and affordable manner.
Auxulin has been tested in an open-label study, where it reduced the duration of hyperglycemia by a factor of three. The time to return to sub-hyperglycemic blood glucose levels dropped from an average of 160 minutes to 50 minutes during numerous experimental treatments. Auxulin is not a stand-alone treatment; it is designed to supplement traditional treatments like insulin to maintain healthy blood sugar levels.
The founders of Auxulin, Tommy, and Gary Ritz, have fully incorporated Auxulin into their blood glucose management and have seen significant improvements in their A1C percentage (a measure of blood sugar control over 3 months). During a four-month period of using Auxulin only when experiencing hyperglycemia, Tommy and Gary's average A1C percentage reduced from 7.6 to 6.5. After a further nine months, Tommy's A1C percentage dropped to 6.3, a lifelong low since diagnosis (25 years).